DHPCs: Writing and Distributing a Safety Letter That Healthcare Professionals Will Act On

A Direct Healthcare Professional Communication is the most visible safety message a marketing authorisation holder sends. It is also one of the most tightly controlled, and the best ones are short, specific and agreed well before the day they are sent.

When a DHPC is used

EU guidance describes the DHPC as a way to send important safety information directly to individual healthcare professionals, usually when action or a change in practice is needed. Typical triggers include suspension or withdrawal for safety reasons, a restricted indication, a new contraindication, a dose change, a significant new warning, or a supply discontinuation with clinical consequences. A DHPC is not a reply to an enquiry from a healthcare professional, and it is not a marketing tool. A competent authority can also require one.

Agreement comes first

The holder does not send a DHPC on its own authority. The text and the communication plan must be agreed with the relevant authority: the EMA, working through its committees, for centrally authorised products; the reference Member State for products authorised through mutual recognition or decentralised procedures; and the national authority for national products. In Greece, that is the EOF for nationally authorised products. Authorities may publish the final DHPC and may issue their own safety announcement, so the timing of distribution is coordinated.

The communication plan

Alongside the letter sits a plan stating who the recipients are, how they will be reached and when. Recipients may include general practitioners, specialists, pharmacists, nurses and professional societies, depending on who prescribes, dispenses or administers the product. Where several holders market the same substance, they coordinate and one usually acts as contact point. The plan also covers translation into national languages, which is often what governs the real timeline.

What a good letter looks like

  • The key message and the requested action appear at the beginning, in plain language.
  • The reason is given with only as much data as the reader needs.
  • Use of the standard EU template, including its headings, is expected.
  • Contact details for further questions are provided, together with the reminder to report adverse reactions.
  • National variants do not contradict a core EU text.

After sending

The work does not end with dispatch. Holders should be able to show that the letter reached its intended audience, and where the effect of the communication matters, may be asked to assess it. DHPCs are often paired with additional risk minimisation tools such as educational material, and the two should be consistent.

How PQRA helps

PQRA can help draft DHPCs and communication plans on the EU template, coordinate the national review and translation steps, and prepare the internal processes so that a safety communication can be executed quickly when it is needed. We can also help assess whether an issue calls for a DHPC at all.

Contact PQRA to discuss your pharmacovigilance system, in Greece and across the EU.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *